We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Roche Adopts Fluofarma’s High-Content Screening Platform

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Roche Adopts Fluofarma’s High-Content Screening Platform"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
Fluofarma which offers services and counseling to the Pharmaceutical industry, announced that it entered into a multi-year agreement with Roche.

The collaboration will be focused on the development and miniaturization of cell based assays using high throughput flow cytometry and on the development of computational models which can be used to improve the predictability of hepatotoxicity and the safety profiling of compounds in liver cells.

Under the terms of the research collaboration and license agreement, Roche and Fluofarma will work together to develop a hepatotoxicity prediction tool based on HCS that may lead to future increased synergies. Financial terms and conditions of the partnership were not disclosed.

Toxicity evaluation is one of the first steps in the drug discovery process and hepatotoxicity is particularly important as the liver plays a central role in transforming and clearing chemicals. By assessing the susceptibility to the toxicity of new agents in early stages, the goal is to minimize/eliminate hepatotoxicity in the development of new drugs and molecules. The new technology developed by this collaboration will potentially help pharmaceutical companies develop safer drugs.

Fluofarma HCS platform is based on automated flow cytometry, confocal imaging and laser scanning cytometry, and enables the functional analysis of several molecular events simultaneously in living cells with a high throughput. Thus Fluofarma’s HCS technologies constitute a drug discovery method that combines cell-based assays with large-scale analysis. The technology developed by Fluofarma is considered crucial to provide relevant information concerning drug safety and efficacy early in the drug discovery process. The use of Fluofarma technology should accelerate the availability of new, more efficient and safer drugs.